Skip to main content

E&C Republicans Seek FDA’s Baby Formula Memos


06.10.22

VIDEO: The Biden Admin is Promising Transparency

Washington, D.C.– The Biden administration has repeatedly promised transparency for how and why it failed to act with urgency to address the baby formula supply shortages. 

WATCH:  

Today, House Energy and Commerce Committee Republican Leader Cathy McMorris Rodgers (R-WA), Health Subcommittee Republican Leader Brett Guthrie (R-KY), and Oversight Subcommittee Republican Leader Morgan Griffith (R-VA) are requesting that the Food and Drug Administration (FDA) show the memos and reports sent to the White House, and be completely transparent with parents who deserve answers.  

This is what we know: 

  • When asked when he alerted the White House of this crisis, FDA Commissioner Robert Califf told the Energy and Commerce Oversight Subcommittee, there were conversations “up and down the chain” in “early February.”
  • Califf stated memos were produced that “give an elegant description of the issues and then concerns.” 
  • On February 16, 2022, FDA submitted “a report to U.S. government (USG) partners on the potential recall and supply chain impacts given the significant market share held by Abbott Nutrition.”
  • HOWEVER, during a roundtable on June 1, 2022, President Joe Biden said that he was NOT briefed about the baby formula shortage and how intense it was until APRIL 2022. 

Parents need  accountability from President Biden. His administration should start by providing the Energy and Commerce Committee the memos and the report that the FDA Commissioner said were provided to the White House.  

Rodgers, Guthrie, and Griffith are requesting the FDA provide: 

  • A copy of the memos sent to the White House, and for the FDA to specify who received these memos and when. 
  • A copy of the February 16, 2022, report to USG partners, and for the FDA to specific who received this report and when.  
  • All communications between the FDA and the White House regarding the formula shortage in February 2022. 

CLICK HERE to the full letter sent to FDA requesting this information. 

Letter